Osiris Therapeutics, Inc. Sustainability Profile
Osiris Therapeutics, Inc., a pioneering leader in regenerative medicine, is headquartered in the United States. Founded in 1992, the company has made significant strides in the development of innovative cellular therapies, particularly in the fields of orthopaedics, wound care, and inflammatory diseases. Osiris is renowned for its unique core products, including the groundbreaking Grafix® and Ovation® lines, which utilise advanced stem cell technology to promote healing and tissue regeneration. These products stand out in the market due to their ability to enhance recovery while minimising complications. With a strong market position, Osiris Therapeutics has achieved notable milestones, including regulatory approvals and partnerships that underscore its commitment to advancing healthcare solutions. The company continues to be at the forefront of the regenerative medicine industry, driving research and development to improve patient outcomes.
DitchCarbon Score
How does Osiris Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Osiris Therapeutics, Inc.'s score of 70 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Osiris Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Smith & Nephew plc, which may influence its climate commitments and reporting practices. While Osiris Therapeutics has not established any documented reduction targets or climate pledges, it is important to note that emissions data and sustainability initiatives may be cascaded from its parent company, Smith & Nephew plc. This relationship could potentially align Osiris with broader corporate sustainability goals and practices. As of now, without specific emissions data or reduction initiatives, Osiris Therapeutics appears to be in the early stages of formalising its climate commitments. The company may benefit from leveraging the sustainability frameworks and targets set by Smith & Nephew to enhance its environmental performance in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 10,123,000 | 00,000,000 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 67,559,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
How Carbon Intensive is Osiris Therapeutics, Inc.'s Industry?
How Carbon Intensive is Osiris Therapeutics, Inc.'s Location?
Osiris Therapeutics, Inc.'s Scope 3 Categories Breakdown
Osiris Therapeutics, Inc.'s Scope 3 emissions, which decreased by 48% last year and decreased by approximately 59% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 73% of Scope 3 emissions.
Top Scope 3 Categories
Osiris Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Osiris Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
